Have a feature idea you'd love to see implemented?
Let us know!
BIIB Biogen Inc
Price (delayed)
$181.72
Market cap
$26.47B
P/E Ratio
22.8
Dividend/share
N/A
EPS
$7.97
Enterprise value
$31.22B
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Highlights
The equity has grown by 10% YoY and by 4.4% from the previous quarter
Biogen's debt has decreased by 4.1% from the previous quarter
The company's quick ratio has shrunk by 50% YoY but it rose by 35% QoQ
The P/E is 28% above the 5-year quarterly average of 18.0 but 19% below the last 4 quarters average of 28.4
Biogen's net income has shrunk by 57% YoY
The EPS has plunged by 57% YoY
Key stats
What are the main financial stats of BIIB
Market
Valuations
Earnings
Shares outstanding
145.66M
Market cap
$26.47B
Enterprise value
$31.22B
Price to book (P/B)
1.67
Price to sales (P/S)
2.74
EV/EBIT
23.74
EV/EBITDA
16.55
EV/Sales
3.23
Revenue
$9.67B
EBIT
$1.31B
EBITDA
$1.89B
Free cash flow
$1.57B
Per share
Balance sheet
Liquidity
EPS
$7.97
Free cash flow per share
$10.79
Book value per share
$109.13
Revenue per share
$66.43
TBVPS
$84.78
Total assets
$26.8B
Total liabilities
$10.92B
Debt
$6.66B
Equity
$15.89B
Working capital
$4B
Debt to equity
0.42
Current ratio
2.29
Quick ratio
1.28
Net debt/EBITDA
2.52
Margins
Efficiency
Dividend
EBITDA margin
19.5%
Gross margin
75.5%
Net margin
12%
Operating margin
13.6%
Return on assets
4.3%
Return on equity
7.7%
Return on invested capital
9%
Return on capital employed
5.5%
Return on sales
13.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIIB stock price
How has the Biogen stock price performed over time
Intraday
-0.95%
1 week
-0.69%
1 month
-6.25%
1 year
-23.39%
YTD
-29.78%
QTD
-6.25%
Financial performance
How have Biogen's revenue and profit performed over time
Revenue
$9.67B
Gross profit
$7.31B
Operating income
$1.31B
Net income
$1.16B
Gross margin
75.5%
Net margin
12%
BIIB's operating income has dropped by 58% year-on-year
Biogen's operating margin has plunged by 57% YoY
Biogen's net income has shrunk by 57% YoY
Biogen's net margin has plunged by 55% YoY
Growth
What is Biogen's growth rate over time
Valuation
What is Biogen stock price valuation
P/E
22.8
P/B
1.67
P/S
2.74
EV/EBIT
23.74
EV/EBITDA
16.55
EV/Sales
3.23
The EPS has plunged by 57% YoY
The P/E is 28% above the 5-year quarterly average of 18.0 but 19% below the last 4 quarters average of 28.4
BIIB's price to book (P/B) is 49% lower than its 5-year quarterly average of 3.3 and 27% lower than its last 4 quarters average of 2.3
The equity has grown by 10% YoY and by 4.4% from the previous quarter
The stock's price to sales (P/S) is 23% less than its last 4 quarters average of 3.6 and 21% less than its 5-year quarterly average of 3.5
Biogen's revenue has decreased by 3% YoY
Efficiency
How efficient is Biogen business performance
The ROE has plunged by 61% YoY and by 2.5% from the previous quarter
Biogen's return on assets has shrunk by 60% YoY and by 2.3% QoQ
The ROS has plunged by 57% YoY
The ROIC has plunged by 50% YoY but it has grown by 7% from the previous quarter
Dividends
What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIIB.
Financial health
How did Biogen financials performed over time
The total assets is 146% more than the total liabilities
The company's quick ratio has shrunk by 50% YoY but it rose by 35% QoQ
The current ratio has contracted by 30% YoY but it has grown by 9% from the previous quarter
Biogen's debt is 58% less than its equity
The equity has grown by 10% YoY and by 4.4% from the previous quarter
The debt to equity has decreased by 9% from the previous quarter and by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.